Topical and intralesional therapies for alopecia areata

Dermatologic Therapy

Volumn 24, Issue 3, 2011, Pages 355-363

  Alkhalifah, Abdullah ^a  

^a Riyadh Military Hospital ^*  (Saudi Arabia)

Author keywords

alopecia areata; corticosteroids; immunotherapy; intralesional; topical

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BETAMETHASONE VALERATE; BEXAROTENE; BIMATOPROST; CAPSAICIN; CLOBETASOL; DESOXIMETASONE; DIPHENCYPRONE; DITHRANOL; FLUOCINOLONE ACETONIDE; HYDROCORTISONE; IMIQUIMOD; LATANOPROST; LATTISSE; MINOXIDIL; PIMECROLIMUS; PSORALEN; SQUARIC ACID DIBUTYL ESTER; TACROLIMUS; THIOREDOXIN REDUCTASE 1; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; ALOPECIA AREATA; APPLICATION SITE IRRITATION; ARTICLE; CERVICAL LYMPHADENOPATHY; CONJUNCTIVAL HYPEREMIA; CONTACT DERMATITIS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; ERYTHEMA MULTIFORME; EYE IRRITATION; FACE EDEMA; FLU LIKE SYNDROME; FOLLICULITIS; HAIR GROWTH; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; HYPOTRICHOSIS; LYMPHADENOPATHY; MULTICENTER STUDY (TOPIC); NAIL DYSCHROMIA; NONHUMAN; OPEN ANGLE GLAUCOMA; PHOTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SKIN ATROPHY; TELANGIECTASIA; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; VITILIGO;

ADMINISTRATION, TOPICAL; AGE FACTORS; ALOPECIA; ALOPECIA AREATA; ANIMALS; FEMALE; GLUCOCORTICOIDS; HAIR FOLLICLE; HUMANS; INJECTIONS, INTRALESIONAL; LYMPHOCYTES; MALE; PHOTOTHERAPY; SEVERITY OF ILLNESS INDEX;

EID: 79959543983     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01419.x     Document Type: Article

References (93)

1. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J,. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010: 62: 177-188, quiz 89-90.
2. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd,. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995: 70: 628-633.
3. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A,. Alopecia areata. Int J Dermatol 2007: 46: 121-131. (Pubitemid 46679412)
4. Price VH,. Alopecia areata: clinical aspects. J Invest Dermatol 1991: 96: 68S.
5. Madani S, Shapiro J,. Alopecia areata update. J Am Acad Dermatol 2000: 42: 549-566, quiz 67-70.
6. Whiting DA,. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003: 139: 1555-1559. (Pubitemid 37523073)
7. Lu W, Shapiro J, Yu M, et al,. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med 2006: 8: 1-19. (Pubitemid 43923144)
8. Paus R, Slominski A, Czarnetzki BM,. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993: 66: 541-554.
9. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J,. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010: 62: 191-202, quiz 3-4.
10. Olsen EA, Hordinsky MK, Price VH, et al,. Alopecia areata investigational assessment guidelines-Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004: 51: 440-447.
11. Pascher F, Kurtin S, Andrade R,. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970: 141: 193-202.
12. Mancuso G, Balducci A, Casadio C, et al,. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003: 42: 572-575. (Pubitemid 36869157)
13. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C,. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003: 49: 96-98. (Pubitemid 36801639)
14. Tosti A, Iorizzo M, Botta GL, Milani M,. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006: 20: 1243-1247. (Pubitemid 44614622)
15. Charuwichitratana S, Wattanakrai P, Tanrattanakorn S,. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000: 136: 1276-1277.
16. Garg S, Messenger AG,. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009: 28: 15-18.
17. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J,. Interventions for alopecia areata. Cochrane Database Syst Rev 2008: 2: CD004413.
18. Abell E, Munro DD,. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973: 88: 55-59.
19. Porter D, Burton JL,. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971: 85: 272-273.
20. Kubeyinje EP,. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994: 71: 674-675.
21. Chang KH, Rojhirunsakool S, Goldberg LJ,. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009: 8: 909-912.
22. Shapiro J, Price VH,. Hair regrowth. Therapeutic agents. Dermatol Clin 1998: 16: 341-356.
23. Sohn KC, Jang S, Choi DK, et al,. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem Biophys Res Commun 2007: 356: 810-815. (Pubitemid 46499039)
24. Wester RC, Maibach HI, Guy RH, Novak E,. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 1984: 82: 515-517. (Pubitemid 14101289)
25. Bunker CB, Dowd PM,. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol 1987: 117: 668-669. (Pubitemid 18078457)
26. Lachgar S, Charveron M, Gall Y, Bonafe JL,. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998: 138: 407-411. (Pubitemid 28145505)
27. Uno H, Cappas A, Brigham P,. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 1987: 16: 657-668. (Pubitemid 17031771)
28. Mori O, Uno H,. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990: 17: 276-281. (Pubitemid 20321655)
29. Buhl AE, Waldon DJ, Conrad SJ, et al,. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992: 98: 315-319.
30. Messenger AG, Rundegren J,. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004: 150: 186-194. (Pubitemid 38352454)
31. Price VH,. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987: 16: 730-736. (Pubitemid 17031782)
32. Fiedler-Weiss VC,. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987: 16: 745-748. (Pubitemid 17031784)
33. Fiedler-Weiss VC, West DP, Buys CM, Rumsfield JA,. Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol 1986: 122: 180-182. (Pubitemid 16130354)
34. Olsen EA, Dunlap FE, Funicella T, et al,. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002: 47: 377-385.
35. Lucky AW, Piacquadio DJ, Ditre CM, et al,. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004: 50: 541-553. (Pubitemid 38393163)
36. Tang L, Cao L, Sundberg JP, Lui H, Shapiro J,. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol 2004: 13: 5-10. (Pubitemid 38165432)
37. Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O,. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979: 115: 1254-1255. (Pubitemid 10153582)
38. Fiedler-Weiss VC, Buys CM,. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987: 123: 1491-1493.
39. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG,. Guidelines for the management of alopecia areata. Br J Dermatol 2003: 149: 692-699. (Pubitemid 37419985)
40. Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL,. Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990: 126: 756-759. (Pubitemid 20193789)
41. Sasmaz S, Arican O,. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol 2005: 6: 403-406. (Pubitemid 43128292)
42. Strobel R, Rohrborn G,. Mutagenic and cell transforming activities of 1-chlor-2,4-dinitrobenzene (DNCB) and squaric-acid-dibutylester (SADBE). Arch Toxicol 1980: 45: 307-314. (Pubitemid 10029601)
43. Summer KH, Goggelmann W,. 1-chloro-2,4-dinitrobenzene depletes glutathione in rat skin and is mutagenic in Salmonella typhimurium. Mutat Res 1980: 77: 91-93. (Pubitemid 10163615)
44. Wilkerson MG, Henkin J, Wilkin JK,. Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability. J Am Acad Dermatol 1984: 11: 802-807. (Pubitemid 15201321)
45. Wilkerson MG, Henkin J, Wilkin JK, Smith RG,. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 1985: 13: 229-234. (Pubitemid 15007116)
46. Happle R,. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980: 267: 109-114. (Pubitemid 10176016)
47. Herbst V, Zoller M, Kissling S, Wenzel E, Stutz N, Freyschmidt-Paul P,. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 2006: 16: 537-542. (Pubitemid 44861829)
48. Happle R, Klein HM, Macher E,. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986: 278: 214-218. (Pubitemid 16106520)
49. Wasylyszyn T, Kozlowski W, Zabielski SL,. Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone. Arch Dermatol Res 2007: 299: 231-237. (Pubitemid 47222921)
50. Hoffmann R, Wenzel E, Huth A, et al,. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994: 103: 530-533. (Pubitemid 24314840)
51. Harries MJ, Sun J, Paus R, King LE Jr,. Management of alopecia areata. BMJ 2010: 341: c3671.
52. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K,. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998: 39: 751-761. (Pubitemid 28519028)
53. Wiseman MC, Shapiro J, MacDonald N, Lui H,. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001: 137: 1063-1068. (Pubitemid 32756464)
54. Orecchia G, Malagoli P, Santagostino L,. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients. Pediatr Dermatol 1994: 11: 65-68. (Pubitemid 24085981)
55. Orecchia G, Malagoli P,. Topical immunotherapy in children with alopecia areata. J Invest Dermatol 1995: 104: 35S-36S.
56. Orecchia G, Perfetti L,. Alopecia areata and topical sensitizers: allergic response is necessary but irritation is not. Br J Dermatol 1991: 124: 509.
57. Dall'oglio F, Nasca MR, Musumeci ML, et al,. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat 2005: 16: 10-14. (Pubitemid 40283317)
58. Gordon PM, Aldrige RD, McVittie E, Hunter JA,. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. Br J Dermatol 1996: 134: 869-871. (Pubitemid 26151401)
59. Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F,. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 2007: 32: 48-51. (Pubitemid 46006366)
60. Francomano M, Seidenari S,. Urticaria after topical immunotherapy with diphenylcyclopropenone. Contact Dermatitis 2002: 47: 310-311. (Pubitemid 36174244)
61. Alam M, Gross EA, Savin RC,. Severe urticarial reaction to diphenylcyclopropenone therapy for alopecia areata. J Am Acad Dermatol 1999: 40: 110-112. (Pubitemid 29051037)
62. Tosti A, Guerra L, Bardazzi F,. Contact urticaria during topical immunotherapy. Contact Dermatitis 1989: 21: 196-197. (Pubitemid 19223037)
63. Perret CM, Steijlen PM, Zaun H, Happle R,. Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica 1990: 180: 5-7. (Pubitemid 20031910)
64. Pan JY, Theng C, Lee J, Goh BK,. Vitiligo as an adverse reaction to topical diphencyprone. Ann Acad Med Singapore 2009: 38: 276-277.
65. Henderson CA, Ilchyshyn A,. Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis. Br J Dermatol 1995: 133: 496-497.
66. Bearden W, Anderson R,. Trichiasis associated with prostaglandin analog use. Ophthal Plast Reconstr Surg 2004: 20: 320-322. (Pubitemid 38971789)
67. Tosti A, Pazzaglia M, Voudouris S, Tosti G,. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004: 51: S149-S150.
68. Hart J, Shafranov G,. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol 2004: 137: 756-757. (Pubitemid 38446695)
69. Herane MI, Urbina F,. Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost. J Eur Acad Dermatol Venereol 2004: 18: 644-645. (Pubitemid 39255773)
70. Sasaki S, Hozumi Y, Kondo S,. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicularmelanogenesis in a murine model. Exp Dermatol 2005: 14: 323-328. (Pubitemid 40691653)
71. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH,. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009: 60: 705-706.
72. Ross EK, Bolduc C, Lui H, Shapiro J,. Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata. J Am Acad Dermatol 2005: 53: 1095-1096. (Pubitemid 41677347)
73. Faghihi G, Andalib F, Asilian A,. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009: 19: 586-587.
74. Coronel-Perez IM, Rodriguez-Rey EM, Camacho-Martinez FM,. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol 2010: 24: 481-485.
75. Ochoa BE, Sah D, Wang G, Stamper R, Price VH,. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol 2009: 61: 530-532.
76. Taylor CR, Hawk JL,. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995: 133: 914-918. (Pubitemid 26009745)
77. Healy E, Rogers S,. PUVA treatment for alopecia areata-does it work? A retrospective review of 102 cases. Br J Dermatol 1993: 129: 42-44. (Pubitemid 23211046)
78. Zakaria W, Passeron T, Ostovari N, Lacour JP, Ortonne JP,. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol 2004: 51: 837-838. (Pubitemid 39516910)
79. Raulin C, Gundogan C, Greve B, Gebert S,. Excimer laser therapy of alopecia areata-side-by-side evaluation of a representative area. J Dtsch Dermatol Ges 2005: 3: 524-526. (Pubitemid 40942635)
80. Gundogan C, Greve B, Raulin C,. Treatment of alopecia areata with the 308-nm xenon chloride excimer laser: case report of two successful treatments with the excimer laser. Lasers Surg Med 2004: 34: 86-90. (Pubitemid 38326349)
81. Al-Mutairi N,. 308-nm excimer laser for the treatment of alopecia areata. Dermatol Surg 2007: 33: 1483-1487. (Pubitemid 350212687)
82. Al-Mutairi N,. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol 2009: 26: 547-550.
83. Talpur R, Vu J, Bassett R, Stevens V, Duvic M,. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009: 61: 592 e1-592 e9.
84. Ehsani AH, Toosi S, Seirafi H, et al,. Capsaicin versus clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol 2009: 23: 1451-1453.
85. Price VH, Willey A, Chen BK,. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005: 52: 138-139. (Pubitemid 40038949)
86. Thiers BH,. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000: 136: 124. (Pubitemid 30038834)
87. Rigopoulos D, Gregoriou S, Korfitis C, et al,. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol 2007: 32: 456-457. (Pubitemid 46828303)
88. Feldmann KA, Kunte C, Wollenberg A, Wolfe H,. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002: 147: 1031-1032. (Pubitemid 35365464)
89. Park SW, Kim JW, Wang HY,. Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Derm Venereol 2002: 82: 387-388.
90. Koc E, Tunca M, Akar A, Kurumlu Z,. Lack of efficacy of topical imiquimod in the treatment of patchy alopecia areata. Int J Dermatol 2008: 47: 1088-1089.
91. D'Ovidio R, Claudatus J, Di Prima T,. Ineffectiveness of imiquimod therapy for alopecia totalis/universalis. J Eur Acad Dermatol Venereol 2002: 16: 416-417. (Pubitemid 34918834)
92. Bissonnette R, Shapiro J, Zeng H, McLean DI, Lui H,. Topical photodynamic therapy with 5-aminolaevulinic acid does not induce hair regrowth in patients with extensive alopecia areata. Br J Dermatol 2000: 143: 1032-1035.
93. Fernandez-Guarino M, Harto A, Garcia-Morales I, Perez-Garcia B, Arrazola JM, Jaen P,. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol 2008: 33: 585-587.